Esophageal cancer is a major health issue.
Chemoprevention is needed to tackle the rising incidence of cases and the poor survival rate.
Marc Bardou and colleagues from Quebec in Canada investigated the effects of the selective cyclooxygenase 2 inhibitors (coxibs), rofecoxib and celecoxib, the nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin on esophageal cancer.
The researchers designed a nested case-control study using data from a government-run insurance database.
The research group included patients of 66 years and older who underwent esophageal imaging (esophagogastroduodenoscopy or barium swallow) between January 1999 and September 2002 in their study.
|Patients more likely to have esophageal cancer were men and older subjects|
|Clinical Gastroenterology and Hepatology|
The team used logistic regression models to determine the effect of chronic exposure, and by using as proxy at least 30 days of use of the drugs of interest in the past year, on the occurrence of esophageal cancer.
The researchers included 251 cases in total and all 86,644 eligible control subjects.
The researchers found that patients more likely to have esophageal cancer were men and older subjects (those 75–84 years and those ≥85 years).
Chronic exposure to coxibs or NSAIDs was associated with a significant risk reduction for esophageal cancer.
The research group then assessed the point estimates separately and found that they were slightly lower for rofecoxib than for celecoxib when examining a possible duration-response effect.
Dr Bardou concluded, "Chronic intake of rofecoxib and celecoxib and of nonselective NSAIDs appears to be associated with a decreased incidence of esophageal cancer."